Anca Mera

Dr. Anca Mera


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in BMC Genomics
Verified
Journal Article
Open access
PDF file
EREmanuele de Rinaldis
Emanuele de Rinaldis
PGPatrycja Gazinska
Patrycja Gazinska
AMAnca Mera
Anca Mera
ZMZora Modrusan
Zora Modrusan
GFGrazyna M Fedorowicz
Grazyna M Fedorowicz
ATAndrew Tutt
Andrew Tutt
This study focuses on the analysis of miRNAs expression data in a cohort of 181 well characterised breast cancer samples composed primarily of triple-negative (ER/PR/HER2-negative) tumours with associated genome-wide DNA and mRNA data, extensive patient follow-up and pathological information.

11 November 2022 in Journal of Cancer Policy
Verified
Journal Article
Open access
Mieke Van HemelrijckMieke Van Hemelrijck
Mieke Van Hemelrijck
LFL. Fox
L. Fox
KBKatharina Beyer
Katharina Beyer
EFE. Fedaraviciute
E. Fedaraviciute
GGG. George
G. George
RSR. Sullivan
R. Sullivan
The invasion of Ukraine by Russia in February 2022 has resulted in destruction of healthcare infrastructure and triggered the largest wave of internally displaced populations and refugees since World War Two. Conflicts in transitioned countries such as Ukraine create new non-communicable disease (NCD) challenges, especially for cancer care for refugees and humanitarian assistance in host countries. In the early days, rapid attempts were made to model possible impacts. By evaluating open source intelligence used in the first three months of the conflict through snowball search methods, we aimed to address: (i) burden of cancer in Ukrainian population, specifically considering translating to the refugees population, and its cancer care capacity; ii) baseline capacity/strengths of cancer systems in initial host countries. Moreover, using a baseline scenario based on crude cancer incidence in Ukraine, and considering data from UNHCR, we estimated how cancer cases would be distributed across host countries. Finally, a surveillance assessment instrument was created, intersecting health system's capacity and influx of internally displaced populations and refugees. The total new cancer patients per month in pre-conflict Ukraine was estimated as 13,106, of which < 1 % are paediatric cases. The estimated cancer cases in the refugee population (combining prevalent and incident), assuming 7.5 million refugees by July 2022 and a female:male ratio of 9:1, was 33,121 individuals (Poland: 19284; Hungary: 3484; Moldova: 2651; Slovakia: 2421; Romania: 5281). According to our assessments, Poland is the only neighbouring country classified as green/yellow for cancer capacity, i.e. sufficient ablility to absorb additional burden into national health system; Slovakia we graded as yellow, Hungary and Romania as yellow/red and Moldova as red.

18 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JTJasmine Timbres
Jasmine Timbres
CMCharlotte Moss
Charlotte Moss
AMAnca Mera
Anca Mera
AHAnna Haire
Anna Haire
CGCheryl Gillett
Cheryl Gillett
ESElinor J. Sawyer
Elinor J. Sawyer
Invasive lobular breast cancer (ILC) accounts for 10–15% of breast cancers and has distinct characteristics compared with the more common invasive ductal carcinoma (IDC). Studies have shown that ILC may be less sensitive to chemotherapy than IDC, with lower rates of complete pathological response after neo-adjuvant chemotherapy, but it is not clear how this affects long-term survival. Patients at Guy’s and St Thomas’ NHS Foundation Trust between 1975 and 2016 diagnosed with ER+ IDC or ER+ ILC were eligible for inclusion. Kaplan–Meier plots and Cox proportional-hazards regression models were used for analysis. There was no difference in overall survival comparing ER+ ILC to ER+ IDC (OR: 0.94, 95% CI: 0.83, 1.04) with a median follow-up time of 8.3 years compared to 8.4 years in IDC. However, ER+HER2− ILC had worse survival compared to ER+HER2− IDC in those that received chemotherapy (OR: 1.46, 95% CI: 1.06, 2.01). Here, median follow-up time was 7.0 years in ILC compared to 8.1 years in IDC. These results indicate worse overall survival after chemotherapy (neo-adjuvant and adjuvant) in ILC compared to ER+HER2− IDC even when correcting for tumour grade, age, size, and nodal involvement, but validation is needed in a larger study population.

1 May 2013 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
APArnie David Purushotham
Arnie David Purushotham
ESEamon Shamil
Eamon Shamil
MCMassimiliano Cariati
Massimiliano Cariati
OAOlorunsola Agbaje
Olorunsola Agbaje
AMAbbas Muhidin
Abbas Muhidin
LHLars Holmberg
Lars Holmberg